Table 4.
vWF/ADAMTS-13 ratio in patients with COVID-19.
| Point of Study | MILD (n = 39) |
MODERATE (n = 65) |
SEVERE (n = 37) |
p-Value |
|---|---|---|---|---|
| vWF/ADAMTS-13 Point 1 | 2.7 ± 3.2 | 5.7 ± 9.7 | 5.6 ± 3.7 | 0.1428 0.1184 *; 0.1054 **; 0.2154 *** |
| vWF:RCo/ADAMTS-13:activity Point 1 | 1.5 ± 1.8 p = 0.0248 ^ |
3.1 ± 2.1 p = 0.0378 ^ |
3.6 ± 2.2 p = 0.0217 ^ |
0.0005 0.0127 *; 0.0097 **; 0.4478 *** |
| vWF/ADAMTS-13 Point 2 | 2.2 ± 1.9 | 6.9 ± 12.3 | 10.3 ± 9.9 | 0.0065 0.0195 *; 0.0054 **; 0.0845 *** |
| vWF:RCo/ADAMTS-13:activity Point 2 | 1.5 ± 1.7 p = 0.0298 ^ |
3.5 ± 2.2 p = 0.0281 ^ |
4.5 ± 2.0 p = 0.0285 ^ |
<0.0001 0.0065 *; 0.0019 **; 0.0498 *** |
M ± SD, ANOVA; *, **, ***—Tukey test (mild vs. moderate, mild vs. severe, moderate vs. severe); ^ Point 1 vs. Point 2 (paired t-test).